Here are seven ways the IRA has made things worse, and why state leaders shouldn’t copy it.

Buy low, sell high. That’s the name of the game for large hospitals participating in the 340B Drug Pricing Program – and patients end up picking up part of the tab.

Lowering prescription drug costs for patients and making access to medicines more equitable are two important priorities for America’s biopharmaceutical research companies.

Biopharmaceutical manufacturers change lives with groundbreaking medicines. The industry supports many jobs – a total of almost 5 million, in fact.

The numbers are in and the 340B Drug Pricing Program is the second largest federal drug program for another year in a row. Unfortunately, hospital systems and the chain pharmacies they contract with are exploiting the program to generate massive profits off the backs of hardworking Americans.

It’s clear that state drug price setting boards could hurt the patients they claim to serve.

There are better ways to lower the cost of prescription drugs that protect access to medicines and the development of new treatments.

A first-of-its-kind analysis found no evidence a new law requiring insurance companies and their pharmacy benefit managers (PBM) to share rebates with patients has an impact on premiums.

While Illinois lawmakers consider a “Health Care Availability and Access Board” (sometimes referred to as a prescription drug affordability board or PDAB), these boards are really code for government price-setting. Illinoisans should be concerned.

As the Colorado Prescription Drug Board continues its affordability reviews, too many crucial issues remain unsolved.

As Nebraska lawmakers consider a prescription drug board, it’s important to know the truth about how government price setting will affect Nebraskans. A price-setting board could limit access to critical medicines while inserting the government between patients and doctors.

Maryland may have been the first state in the country to establish a so-called prescription drug affordability board (PDAB), but Marylanders will unfortunately continue to see the failures of government price setting as the board progresses.

Instead of adopting flawed price-setting schemes, states should implement common-sense reforms to make insurance work like insurance to safeguard patient access and affordability for the medicines their doctors prescribe.

Comprehensive reform at the federal level is needed. Congress, not states, should put an end to the abuse of this important safety-net program and put it back on track for the patients it was meant to assist.

Patients need better access and affordability when it comes to their medicines, not an unelected board of government bureaucrats making decisions about their medicine's value.

In comments submitted last week, PhRMA cautions CMS about sweeping policy changes to the Medicaid drug rebate program, many of which are not grounded in the Medicaid statute and would go beyond CMS’ legal authority.

Watch this video to hear more findings from the fourth Patient Experience Survey.

After roughly $2 million, several years and the use of flawed data, Colorado is now enabling unelected bureaucrats to set medicine prices through its so-called “Prescription Drug Affordability Board” (PDAB).

The latest PES highlights the barriers between patients and medicines and risks to future innovative treatments.

In 2021, 53% of the $85.6 billion in APIs used in U.S.-consumed medicines were produced in the United States.

Diabetes can be well-managed with comprehensive access to health care services, including medicines.

Research insights from a survey of all 50 states and 435 congressional districts shows opposition to price setting when Americans learn about trade-offs.

A new 50-state poll conducted by Morning Consult on behalf of PhRMA finds 86% of adults in every state agree lowering out-of-pocket costs for health care should be a top policy priority for policymakers.

Indiana just joined West Virginia and Arkansas in delivering an important win for Hoosiers who are struggling to afford their medicines. This week, Governor Holcomb signed into law Senate Bill 8 recently passed by the Indiana legislature.

When asked about policy solutions that their state could pursue to address prescription drug costs, strong majorities of adults favor laws that would require all health insurance plans to cover certain medications used to treat chronic conditions from day one of the plan year (81%) and that would require health insurance companies and their middlemen to pass the rebates and discounts they receive to patients (80%).

States need to act quickly to ensure Americans still have access to affordable health care, including coverage for lifesaving medications.

No one should struggle to access or afford the medicines they need, and last week, Arkansas took a big step forward in making sure that’s not the case.

To turn that tide, we need new treatments and cures that both extend life and improve it. Fortunately, America’s biopharmaceutical research companies are working to find innovative solutions that can help patients across the United States.

Over the 30 years since the 340B program was created, it has devolved from one that could have made health care more equitable through improved access to medicines for vulnerable communities to one that has resulted in disparities in how certain populations access care.

It often doesn’t feel that way for patients because insurers and pharmacy benefit managers (PBMs) have increasingly shifted more out of pocket costs on medicines to many patients through high deductibles and coinsurance. So while health plans routinely base patient cost sharing for services like hospital stays and doctor visits on the negotiated prices the health plans pay, they receive with patients, when it comes to life saving medicines, that’s often not the case.

Delaware just made took an important step to protect patient assistance.

West Virginia took a big step towards making insurance work like it should last week

Medicaid provides health coverage for low-income and disabled individuals, and is jointly funded by state and federal governments.

Biopharmaceutical research and clinical trials are taking place across the U.S. every day. Explore the interactive map below and select a state to access data on biopharmaceutical jobs, the industry's overall economic impact, clinical trial activity and more.

It’s time to put people over the bottom line. States can require PBMs, insurers and other middlemen to put patients first.

States can enact legislation today requiring insurers and PBMs to share the rebates they negotiate from manufacturers with individual patients.

Scientists and researchers are committed to improving treatment while ensuring that medicines remain accessible. Learn more about the factors that determine the cost and value of treatment.

Through partnerships across the country, the PhRMA Equity Initiative is committed to creating a more representative workforce and equitable health care system.

America’s biopharmaceutical companies turned a once in a generation challenge into reality by delivering safe and effective COVID-19 vaccines and treatments to patients in record time.

Polling and data insights are critical to informing and understanding how we can develop proactive public policies that address the needs of patients. We are committed to listening to patient voices and drawing key insights from public opinion research to help shape the conversation surrounding these key issues.